Successful Etanercept Therapy for Refractory Sacroiliitis in a Patient with Ankylosing Spondylitis and Mixed Connective Tissue Disease.
10.3349/ymj.2008.49.1.159
- Author:
Jee Young LEE
1
;
Hyun Kyu CHANG
;
Seong Kyu KIM
Author Information
1. Department of Diagnostic Radiology, College of Medicine, Dankook University, Cheonan, Korea. kimsk714@cu.ac.kr
- Publication Type:Case Report
- Keywords:
Ankylosing spondylitis;
mixed connective tissue disease;
etanercept
- MeSH:
Female;
Humans;
Immunoglobulin G/*therapeutic use;
Magnetic Resonance Imaging;
Middle Aged;
Mixed Connective Tissue Disease/complications/*drug therapy/*pathology;
Receptors, Tumor Necrosis Factor/*therapeutic use;
Sacroiliac Joint/*drug effects/*pathology;
Spondylitis, Ankylosing/complications/*drug therapy/*pathology;
Treatment Outcome
- From:Yonsei Medical Journal
2008;49(1):159-162
- CountryRepublic of Korea
- Language:English
-
Abstract:
The concurrence of ankylosing spondylitis (AS) in a patient with mixed connective tissue disease (MCTD) is rarely described in the literature. Significant and sustained efficacy with tumor necrosis factor (TNF)-alpha blockers has been demonstrated in AS patients. However, evidence to date has revealed associated side effects, including antinuclear antibody induction and development of a lupus-like syndrome. Several authors have reported lupus-like manifestations in MCTD patients treated with TNF-alpha blockers used to control peripheral polyarthritis. In our case report, we demonstrate a good response to etanercept therapy for refractory sacroiliitis in a patient with coexisting AS and MCTD, without development of a lupus-like syndrome. This demonstrates that etanercept therapy may be an appropriate therapeutic agent for sacroiliitis in MCTD patients, as it is in AS alone.
